Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts
- 14 October 2013
- journal article
- research article
- Published by Taylor & Francis in AIDS Care
- Vol. 26 (6) , 684-693
Abstract
In 2010, the centre for the AIDS Programme of Research in South Africa (CAPRISA)004 and iPrEx trials (microbicide gel containing tenofovir and oral pill containing tenofovir–emtricitabine, respectively) demonstrated that antiretroviral preexposure prophylaxis (PrEP) reduced the risk of HIV acquisition among high-risk individuals. To determine the facilitators and barriers to PrEP provision by health-care providers, we conducted an online, quantitative survey of Massachusetts-area physicians following the publication of the CAPRISA and iPrEx results. We assessed awareness and comprehension of efficacy data, prescribing experience, and anticipated provision of oral and topical PrEP among physicians, as well as demographic and behavioral factors associated with PrEP awareness and prescribing intentions. The majority of HIV specialists and generalist physicians were aware of data from these PrEP trials and able to correctly interpret the results, however, correct interpretation of findings tended to vary according to specialty (i.e., HIV specialists had greater awareness than generalists). In addition, provider concerns regarding PrEP efficacy and safety, as well its ability to divert funds from other HIV prevention resources, were associated with decreased intentions to prescribe both oral and topical PrEP. Findings suggest that a substantial proportion of physicians who may have contact with at-risk individuals may benefit from interventions that provide accurate data on the risks and benefits of PrEP in order to facilitate effective PrEP discussions with their patients. Future studies to develop and test interventions aimed at health-care providers should be prioritized to optimize implementation of PrEP in clinical settings.Keywords
This publication has 17 references indexed in Scilit:
- A Qualitative Study of Provider Thoughts on Implementing Pre-Exposure Prophylaxis (PrEP) in Clinical Settings to Prevent HIV InfectionPLOS ONE, 2012
- Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex WorkersPLOS ONE, 2012
- Preexposure Prophylaxis for HIV InfectionSouthern Medical Journal, 2012
- Physician Awareness of Sexual Orientation and Preventive Health Recommendations to Men Who Have Sex With MenSexually Transmitted Diseases, 2011
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with MenNew England Journal of Medicine, 2010
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- HIV, transmitted drug resistance, and the paradox of preexposure prophylaxisProceedings of the National Academy of Sciences, 2010
- HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐EffectivenessClinical Infectious Diseases, 2009
- How numeracy influences risk comprehension and medical decision making.Psychological Bulletin, 2009
- Estimation of HIV Incidence in the United StatesJAMA, 2008